Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now NasdaqGM - Delayed Quote • USD XOMA Royalty Corporation (XOMAP) Follow Compare 25.74 +0.22 +(0.86%) At close: 4:00:00 PM EDT Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for XOMAP 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: XOMAP View More All News Press Releases SEC Filings XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference XOMA Royalty Declares Quarterly Preferred Stock Dividends XOMA Royalty Full Year 2024 Earnings: EPS Misses Expectations XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements XOMA Royalty Corporation's (NASDAQ:XOMA) largest shareholders are retail investors with 38% ownership, institutions own 36% XOMA Royalty to Present at Investor Conferences in March XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio What Makes XOMA Royalty (XOMA) a New Buy Stock XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags